Sabinsa launches turmeric extract for weight management and inflammation

28 Feb 2022 --- Health science company Sabinsa is releasing a turmeric extract, CurCousin. It contains bioactive Calebin A, a curcumin analog naturally present in Curcuma longa and Curcuma caesia. The dietary ingredient may be suitable for metabolic syndrome, obesity, inflammation, diabetes, osteoporosis and liver health management.

CurCousin aids in balancing cholesterol and it also supports healthy blood sugar levels and blood circulation. According to Sabinsa, it supports a healthy body weight by inhibiting adipogenesis (fat cells).

Sabinsa holds 65 US and international patents on this product, which has self-affirmed GRAS status.

A Sabinsa clinical study found that Calebin A effectively manages healthy body weight by inhibiting adipogenesis, making it an ingredient to support metabolic health.

Investigating the effectiveness of Calebin A
A published study led by Dr. Muhammed Majeed, founder and chairman at Sabinsa, evaluated the clinical efficacy and safety of Calebin A in managing weight in 40 obese or overweight individuals for 90 days.

The participants were administered Calebin A capsules (25 mg, one capsule twice a day). Significant reductions in body weight and body mass index were observed in the Calebin A group compared with placebo after 90 days.CurCousin helps to balance cholesterol and support healthy blood sugar levels.

Additionally, a significant change in serum biomarkers like leptin, adiponectin and cortisol was observed in the participants, with improved blood lipid profiles. Moreover, Calebin A was safe and well-tolerated by all study subjects.

“Deep knowledge of curcumin has resulted in ingredients like Curcumin C3 Complex,” says Dr. Majeed. “We are enthusiastic about the potential of CurCousin and eager to share details about it with our customers across the world.”

Reducing fat deposition
A separate study found that CurCousin effectively prevented body weight gain and adiposity caused by a high-fat diet.

CurCousin administration lowered fat depositing adipocyte development and prevented lipid accumulation in 3T3-L1 adipocytes (cell line derived from a mouse) by reducing cell numbers. CurCousin also caused lipolysis in differentiated adipocytes in mice on a high-fat diet.

Researchers note that obesity is caused by excessive fat buildup in adipocytes in the form of triglycerides due to high-calorie diets and inactive lifestyles. Obesity is often linked to chronic inflammation, metabolic and vascular changes, all of which contribute to the development of metabolic syndrome.

CurCousin’s release comes when products with good bioavailability are experiencing increased consumer demand.

Previously The European Product Safety Authority (EFSA) approved Sabinsa’s Curcumin C3 Reduct powder as a novel food, allowing for EU sales.

By Nicole Kerr